Martin Falbisoner / Wikimedia Commons
Why It Matters
The Centers for Medicare & Medicaid Services has issued a new federal rule that will reshape how states’ Medicaid and Children’s Health Insurance Program funds can be spent on youth medical care. Idaho, like all states receiving federal Medicaid dollars, must comply with the directive, which takes effect October 13 and will affect how the state’s Medicaid program and CHIP coverage operates for minors seeking gender-affirming medical treatment.
What the Rule Says
The new regulation prohibits state Medicaid plans from covering gender-affirming procedures for children under 18. CHIP funds cannot be used for such care for children under 19. The banned treatments include puberty blockers, cross-sex hormones, and surgical procedures. Mental health services remain available to covered children under both programs.
Current Medicaid and CHIP patients already receiving hormone therapy may continue treatment for up to six months after the rule takes effect, creating a transition period for existing cases.
The Trump Administration’s Position
The Trump administration framed the rule as a protective measure, with Health and Human Services Secretary Robert F. Kennedy Jr. stating that gender-affirming procedures carry serious risks and cause irreversible harm to young people. The administration characterized the procedures as dangerous for minors, viewing the federal restriction as necessary safeguards.
Medical Disagreement
Major medical organizations have affirmed the safety of gender-affirming care for youth. The American Medical Association and the American Academy of Pediatrics have both stated that such treatments are safe and can improve mental health outcomes for appropriate candidates. Dr. Susan Kressly, president of the American Academy of Pediatrics, told the federal agency that “these rules are a baseless intrusion into the patient-physician relationship.”, as first reported by the Idaho Capital Sun
Surgical gender-affirming care for children is extremely rare, according to available data, meaning the practical scope of the rule’s impact on surgical procedures may be limited.
By the Numbers
- October 13, 2026: effective date of the new federal rule
- Age 18: minimum age for Medicaid coverage eligibility under the new rule
- Age 19: minimum age for CHIP coverage eligibility under the new rule
- 6 months: grace period for current patients to continue hormone therapy after the rule takes effect
What Happens Next
Idaho’s state Medicaid agency will need to update its coverage policies and communicate changes to providers and beneficiaries. States have until the October 13 effective date to align their programs with the federal requirement. Idaho enrollees currently receiving gender-affirming hormone treatment will have the six-month window to continue care before coverage ends under state Medicaid and CHIP plans.
The rule represents a significant shift in federal policy on youth medical care, with the Trump administration moving to restrict a category of treatment that prior administrations had permitted under state discretion. The decision sets a clear federal standard that supersedes any state-level policies allowing coverage.
About the Author
